Cigna Group (CI)
(Delayed Data from NYSE)
$262.23 USD
-5.15 (-1.93%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $266.27 +4.04 (1.54%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Cigna Group has a PEG ratio of 0.85 compared to the Medical - HMOs industry's PEG ratio of 1.11.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CI 262.23 -5.15(-1.93%)
Will CI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CI
Why Cigna (CI) is a Great Dividend Stock Right Now
Cigna Q2 Earnings Beat Estimates on Higher Specialty Volumes
CI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cigna (CI) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Cigna (CI) Surpasses Q2 Earnings and Revenue Estimates
Cigna to Report Q2 Earnings: Can Evernorth Offset Healthcare Weakness?
Other News for CI
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Cigna (CI): Truist Adjusts Price Target, Maintains Buy Rating
5 Dividend Stocks With Solid Returns And More Growth Ahead
Cigna (CI) Target Price Lowered by Oppenheimer Despite Positive Growth
Cigna price target lowered by $30 at Truist, here's why